98%
921
2 minutes
20
Objectives: To create an evidence- and expert-informed clinical care pathway focused on identifying and treating depressive symptoms and disorders in long-term care (LTC) residents.
Design: Modified Delphi survey.
Setting And Participants: Delphi participants were LTC health care providers, LTC administrators, friend/family caregivers of residents living in LTC, and residents of LTC.
Methods: Initial survey statements were developed based on evidence and expert opinion. The survey was distributed in as many rounds as required to reach agreement among participants. Survey participants used Likert scale responses to rate their agreement with each statement describing a step of the clinical care pathway. Statements were revised between rounds based on participant feedback and median and interquartile range values.
Results: To reach a consensus among participants on statements, 2 rounds of survey distribution were required. Twenty-six participants completed both rounds of the survey. Statements were organized into 4 categories: depression detection, identifying contributors to depression, symptom management, and coordination of care. Clinicians identified critical statements that were considered foundational to pathway function.
Conclusions And Implications: The generated statements provide steps for identifying and managing depression among residents of LTC. These steps can be further tested in practice Canada-wide to improve care for residents. Steps that detail care outside current practice, such as staff education on depression detection and access to nonpharmacologic treatments, may require additional resources. During statement revisions, participants disagreed on when depression should be assessed, how validated depression assessment tools should be used, and how to account for depressive history and comorbidities as part of management. Further research is required to understand the barriers to providing care for depression before pathway implementation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jamda.2025.105791 | DOI Listing |
J Eval Clin Pract
September 2025
Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan.
Background: Chest radiography is often performed preoperatively as a common diagnostic tool. However, chest radiography carries the risk of radiation exposure. Given the uncertainty surrounding the utility of preoperative chest radiographs, physicians require systematically developed recommendations.
View Article and Find Full Text PDFAdv Sci (Weinh)
September 2025
Key Laboratory of Emergency and Trauma of Ministry of Education, The First Affiliated Hospital, NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine & The Second Affiliated Hospital, Hainan Medical University, Haikou, 571199, China.
Circulating tumor cells (CTCs) carry intact tumor molecular information, making them invaluable for personalized cancer monitoring. However, conventional capture methods, relying on passive diffusion, suffer from low efficiency due to insufficient collision frequency, severely limiting clinical utility. Herein, a magnetic micromotor-functionalized DNA-array hunter (MMDA hunter) is developed by integrating enzyme-propelled micromotors, magnetic nanoparticles, and nucleic acid aptamers into distinct functional partitions of a DNA tile self-assembly structure.
View Article and Find Full Text PDFGenet Med
September 2025
Division of Medical Genetics, University of Washington School of Medicine.
Purpose: The fourth phase of the Electronic Medical Records and Genome Network (eMERGE4) is testing the return of 10 polygenic risk scores (PRS) across multiple clinics. Understanding the perspectives of health-system leaders and frontline clinicians can inform plans for implementation of PRS.
Methods: Fifteen health-system leaders and 20 primary care providers (PCPs) took part in semi-structured interviews.
Med J Aust
September 2025
Sydney School of Public Health, the University of Sydney, Sydney, NSW.
Objectives: To assess changes in greenhouse gas emission rates associated with the use of anaesthetic gases (desflurane, sevoflurane, and isoflurane) in Australian health care during 2002-2022, overall and by state or territory and hospital type.
Study Design: Retrospective descriptive analysis of IQVIA anaesthetic gases purchasing data.
Setting: All Australian public and private hospitals, 1 January 2002 - 31 December 2022.